Certara Creates Global Strategic Modeling and Simulation Consultancy
Certara®, a global biosimulation technology-enabled drug development company, announced the merger of its consulting group, Pharsight Consulting Services.
Certara®, a global biosimulation technology-enabled drug development company, announced the merger of its consulting group, Pharsight Consulting Services (PCS), with Quantitative Solutions, a global pharmacometrics consulting company headquartered in Menlo Park, Calif. The resulting organization is called Certara Strategic Consulting.
This transaction increases Certara’s broadens the company’s modeling capabilities by adding model-based meta-analysis (MBMA) – which uses highly-curated clinical trial data and parametric pharmacology models to increase drug development productivity, quantitatively inform portfolio management, and improve clinical trial success. Another asset is the clinical outcomes databases for analyzing the comparative effectiveness of a new drug within its competitive landscape. Certara has four business units – Certara Strategic Consulting, Certara Software, Simcyp (which focuses on PBPK), and Synchrogenix (which specializes in regulatory writing).
Read the full release here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
